Business Context and Reporting Period
This Form 8-K Current Report from Armata Pharmaceuticals, Inc. (ARMP) covers the period ending July 31, 2024, with the report filed on August 15, 2024. The filing primarily addresses Item 5.02 regarding the appointment of a new Senior Vice President, Finance, and the transition of the Principal Financial Officer role.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on executive compensation and personnel changes.
- Base Salary: $350,000 annually for the new Senior Vice President, Finance.
- Target Bonus: 40% of base salary, contingent on performance.
- Equity Grant: Option to purchase 75,000 shares of common stock, vesting in equal annual installments over four years.
Material Changes
The primary material change is the appointment of David House as Senior Vice President, Finance, effective August 16, 2024. Concurrently, Richard Rychlik will transition from Principal Financial Officer to Vice President, Corporate Controller. No financial performance changes or material asset transactions are reported in this document.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or discussion of general business risks. It details specific employment terms, including severance provisions: six months of base salary continuation (or 12 months if terminated during a Change in Control Protection Period) and full acceleration of unvested equity awards if termination occurs during the Change in Control Protection Period.
Investor Verification Checklist
- Verify the effective date of David House's appointment (August 16, 2024) and the transition of Richard Rychlik's role.
- Review the full Employment Letter Agreement (Exhibit 10.1) for detailed definitions of "cause," "good reason," and the "Change in Control Protection Period."
- Confirm the vesting schedule and exercise price of the 75,000 share option grant under the 2016 Equity Incentive Plan.
- Check subsequent filings for the company's most recent financial statements, as this 8-K does not contain financial data.